CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

Hyun Jung Lee, Dae-Seog Heo, Joo-Youn Cho, Sae-Won Han, Hye-Jung Chang, Hyeon-Gyu Yi, Tae-Eun Kim, Se-Hoon Lee, Do-Youn Oh, Seock-Ah Im, In-Jin Jang, Yung-Jue Bang

Cancer Research and Treatment. 2014;46(3):234-242. Published online 2014 July 15 DOI: https://doi.org/10.4143/crt.2014.46.3.234

A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer

Hyun Jung Lee, Dae-Seog Heo, Joo-Youn Cho, Sae-Won Han, Hye-Jung Chang, Hyeon-Gyu Yi, Tae-Eun Kim, Se-Hoon Lee, Do-Youn Oh, Seock-Ah Im, In-Jin Jang, Yung-Jue Bang

Cancer Research and Treatment. 2014;46(3):234-242

Link1

Link2

359 Phase Ib and pharmacokinetic studies of Everolimus (RAD001), a novel oral mTOR-inhibitor, with paclitaxel in patients with advanced solid tumors

M. Campone, V. Levy, V. Delecroix, E. Bourbouloux, D. Bootle, C. Tanaka, N. Shand, F. Calvo, E. Raymond

European Journal of Cancer Supplements. 2004;2(8):108

Link1 Link2

A phase I study of Ro 31-7453, a novel oral cell cycle inhibitor, in combination with paclitaxel: final results

European Journal of Cancer. 2002;38:S49

Link1 Link2

Preliminary results of an ongoing phase I and pharmacokinetic study of CYC202, a novel oral cyclin-dependent kinases inhibitor, in patients with advanced malignancies

European Journal of Cancer. 2002;38:S49

Link1 Link2

Phase I, pharmacokinetic (PK) and biologic study of OSI-774, a selective epidermal growth factor receptor (EGFR) tyrosine kinase (TK) inhibitor in combination with paclitaxel and carboplatin in patients with advanced solid malignancies

European Journal of Cancer. 2002;38:S54

Link1 Link2

1472 POSTER A phase I study with fosfluridine tidoxil, a novel oral fluoropyrimidine, in patients with advanced solid tumors

European Journal of Cancer Supplements. 2005;3(2):426

Link1 Link2

First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiogenic agent, in patients with advanced solid tumours

European Journal of Cancer. 2002;38:S17

Link1 Link2

1202 ORAL A Phase I Study of the Potent AKT Inhibitor MK-2206 in Combination With Carboplatin and Paclitaxel, Docetaxel or Erlotinib in Patients With Advanced Solid Tumours

L.R. Molife, S. Minton, J. Vitfell-Pedersen, E. Chen, D. Sullivan, L. Yan, A.M. Zernhelt, L. Siu, J.S. de Bono, A.W. Tolcher

European Journal of Cancer. 2011;47:S144-S145

Link1 Link2

1448 ORAL Molecular pharmacodynamic (MPD) phase I study with serial tumor and skin biopsies of the oral mTOR inhibitor Everolimus (E, RAD001) at different doses and schedules in patients (pts) with advanced solid tumors

European Journal of Cancer Supplements. 2005;3(2):419

Link1 Link2

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer

Kim N. Chi, Stephen K. Chia, Ross Dixon, Michael J. Newman, Vince J. Wacher, Branimir Sikic, Karen A. Gelmon

Investigational New Drugs. 2005;23(4):311-315

Link1

Link2 Link3 Link4

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.